These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33944986)

  • 1. Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes in a real-life setting.
    Chevallard M; Belloli L; Ughi N; Adinolfi A; Casu C; Di Cicco M; Filippini DA; Muscarà M; Schito E; Verduci E; Gentile MG; Di Rosa B; Zoppini L; Carli C; Destefani C; Luisi A; Vincenti EM; Epis OM
    Rheumatol Int; 2021 Jul; 41(7):1253-1261. PubMed ID: 33944986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study.
    Miler M; Nikolac Gabaj N; Grazio S; Vahtarić A; Vrtarić A; Grubišić F; Skala Kavanagh H; Doko Vajdić I; Vrkić N
    Rheumatol Int; 2020 Sep; 40(9):1455-1461. PubMed ID: 32462255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.
    Ciurea A; Papagiannoulis E; Bürki K; von Loga I; Micheroli R; Möller B; Rubbert-Roth A; Andor M; Bräm R; Müller A; Dan D; Kyburz D; Distler O; Scherer A; Finckh A
    Ann Rheum Dis; 2021 Feb; 80(2):238-241. PubMed ID: 32963052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases.
    Sheahan A; Anjohrin S; Suruki R; Stark JL; Sloan VS
    Clin Rheumatol; 2024 Jun; 43(6):1897-1907. PubMed ID: 38658403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effects of complex multimodal rheumatologic treatment in the Rheumatology Center, Rhineland-Palatinate].
    Triantafyllias K; Sauer C; Schwarting A
    Z Rheumatol; 2022 Sep; 81(7):596-604. PubMed ID: 35532799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
    Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.
    Migkos MP; Kaltsonoudis E; Pelechas E; Drossou V; Karagianni PG; Kavvadias A; Voulgari PV; Drosos AA
    Rheumatol Int; 2021 May; 41(5):903-909. PubMed ID: 33655421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
    Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.
    Ferri C; Giuggioli D; Raimondo V; L'Andolina M; Tavoni A; Cecchetti R; Guiducci S; Ursini F; Caminiti M; Varcasia G; Gigliotti P; Pellegrini R; Olivo D; Colaci M; Murdaca G; Brittelli R; Mariano GP; Spinella A; Bellando-Randone S; Aiello V; Bilia S; Giannini D; Ferrari T; Caminiti R; Brusi V; Meliconi R; Fallahi P; Antonelli A;
    Clin Rheumatol; 2020 Nov; 39(11):3195-3204. PubMed ID: 32852623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.